Praxis Precision Medicines Investor Relations Material

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying insights from genetic epilepsies to both rare and more prevalent neurological disorders. The company has has established a broad portfolio with multiple programs, including product candidates across movement disorders, epilepsy and psychiatric disorders, including several clinical-stage product candidates. Praxis was founded in 2015, and is headquartered in Boston, Massachusetts, United States.